99455-15-9

Usage

Uses

Used in Pharmaceutical Industry:
7-Bromo-2-chloro-quinoline is used as an intermediate in the synthesis of various pharmaceuticals. Its unique chemical properties make it a valuable component in the development of new drugs and medications.
Used in Agrochemical Industry:
7-BROMO-2-CHLORO-QUINOLINE is also utilized as an intermediate in the production of agrochemicals, contributing to the development of effective pesticides and other agricultural chemicals.
Used in Dye and Pigment Manufacturing:
7-Bromo-2-chloro-quinoline is used in the manufacturing of dyes and pigments, where its light yellow color and chemical properties are harnessed to create a wide range of colorants for various applications.
Used in Organic Synthesis:
As a versatile building block, 7-Bromo-2-chloro-quinoline is employed in organic synthesis for the creation of various chemical compounds, showcasing its broad utility in the chemical industry.
Precaution:
It is important to handle 7-Bromo-2-chloro-quinoline with care, as it can be harmful if ingested or inhaled and can cause irritation to the skin and eyes. Proper safety measures should be taken during its use and storage to ensure the well-being of individuals working with 7-BROMO-2-CHLORO-QUINOLINE.

InChI:InChI=1/C9H5BrClN/c10-7-3-1-6-2-4-9(11)12-8(6)5-7/h1-5H

Upstream product

• 99465-10-8 7-bromo-1,2-dihydroquinolin-2-one 
• 99465-10-8 7-bromo-quinolin-2-ol 
• 917341-34-5 (2E)-N-(3-bromophenyl)-3-phenylprop-2-enamide 
• 99465-09-5 5-bromoquinolin-2(1H)-one 
• 163485-85-6 7-Trimethylstannylquinoline 
• 591-19-5 m-Bromoaniline 
• 99465-18-6 (E)-N-(3-bromophenyl)-3-ethoxypropenamide 
• 349426-35-3 N-(3-bromophenyl)cinnamamide 

Downstream Products

• 445041-75-8 (R)-(+)-2-{4-[(7-bromo-2-quinolinyl)oxy]phenoxy}propionic acid 
• 1223559-68-9 7-bromo-2-ethoxyquinoline 
• 1509899-61-9 (R)-1-(7-bromoquinolin-2-yl)ethan-1-ol 

Relevant academic research and scientific papers

Synthesis and molecular modeling study of new trimeric quinoline derivatives

Di- and trimeric quinoline derivatives have been recently described as potential modulators of Bcl-2 family protein interactions. However, only a few trimeric compounds have been described so far and an enlargement of the number of analogs of this class is needed to expand the structure-activity relationship study. Therefore, the synthesis of six new trimeric quinoline derivatives is reported. Moreover molecular modeling experiments were performed to study the conformational arrangement of compound 36 in Bak binding site of Bcl-x L, showing that these compounds could be potential ligands for Bcl-xL.

From fragment screening to in vivo efficacy: Optimization of a series of 2-aminoquinolines as potent inhibitors of beta-site amyloid precursor protein cleaving enzyme 1 (bace1)

Using fragment-based screening of a focused fragment library, 2-aminoquinoline 1 was identified as an initial hit for BACE1. Further SAR development was supported by X-ray structures of BACE1 cocrystallized with various ligands and molecular modeling studies to expedite the discovery of potent compounds. These strategies enabled us to integrate the C-3 side chain on 2-aminoquinoline 1 extending deep into the P2′ binding pocket of BACE1 and enhancing the ligand's potency. We were able to improve the BACE1 potency to subnanomolar range, over 106-fold more potent than the initial hit (900 μM). Further elaboration of the physical properties of the lead compounds to those more consistent with good blood-brain barrier permeability led to inhibitors with greatly improved cellular activity and permeability. Compound 59 showed an IC50 value of 11 nM on BACE1 and cellular activity of 80 nM. This compound was advanced into rat pharmacokinetic and pharmacodynamic studies and demonstrated significant reduction of Aβ levels in cerebrospinal fluid (CSF).

Synthesis and in vitro antiproliferative activities of quinoline derivatives

The synthesis of new di- and trimeric quinoline derivatives is described as well as their in vitro antiproliferative activities toward a human fibroblast primary culture and two human solid cancer cell lines (MCF-7 and PA 1).

2-QUINOLINONE AND 2-QUINOXALINONE- DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS

The present invention relates to compounds of Formula (I) : and pharmaceutically acceptable salts thereof, to their use in the treatment of bacterial infections, and to their methods of preparation.

PROCESS FOR THE PREPARATION OF (2R)-2-[4-(7-BROMO-2-QUINOLYLOXY)PHENOXY]PROPANOIC ACID

Industrially applicable process for preparing (2R)-2-[4-(7-bromo-2-quinolyloxy)phenoxy] propanoic acid, and salts thereof.

COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS

The present invention relates to compounds that demonstrate antibacterial activity, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans. In particular this invention relates to compounds useful for the treatment of bacterial infections in warm-blooded animals such as humans, more particularly to the use of these compounds in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans.

II. Synthesis and biological evaluation of some bioisosteres and congeners of the antitumor agent, 2-{4-[(7-chloro-2-quinoxalinyl)oxylphenoxy}propionic acid (XK469)

XK469 (1) is among the most highly and broadly active antitumor agents to have been evaluated in our laboratories. Subsequent developmental studies led to the entry of (R)-(+) 1 (NSC 698215) into phase 1 clinical trials (NIH UO1-CA62487). The antitumor me

Synthesis, SAR and in vivo activity of novel thienopyridine sulfonamide pyrrolidinones as factor Xa inhibitors

Thienopyridine sulfonamide pyrrolidinones were found to be potent and selective inhibitors of the coagulation cascade enzyme factor Xa. SAR studies led to several compounds that were selected for further in vivo investigation. These novel aryl binding pocket moieties represent a structural modification to a series of fXa inhibitors. Several compounds proved to be efficacious iv antithrombotic agents.

2(1H)-Quinolinones with cardiac stimulant activity. 1. Synthesis and biological activities of (six-membered heteroaryl)-substituted derivatives

A series of (six-membered heteroaryl)-substituted 2(1H)-quinolinones was synthesized, and structure-activity relationships for cardiac stimulant activity were determined. Most compounds were prepared by acidic hydrolyisis of a heteroaryl-2-methoxyquinoline obtained by palladium-catalyzed cross-coupling methodology. Direct reaction of a pyridinylzinc reagent with a 6-haloquinolinone also proved successful. In anesthetized dogs, 6-pyridin-3-yl-2(1H)-quinolinone (3; 50 μg/kg) displayed greater inotropic activity (percentage increase in dP/dt max) than positional isomers, and potency was maintained with either mono- or di- alkylpyridinyl substituents. Introduction of a 4- or 7- methyl group into 3 reduced inotropic activity, whereas the 8-isomer proved to be the most potent member of the series. Compound 26 and the 2,6-dimethylpyridinyl analogue (27 were approximately 6 and 3 times more potent than milrinone. Several quinolinones displayed positive inotropic activity (decrease in QA interval) in conscious dogs after oral administration (1 mg/kg), and 26, 27 were again the most potent members of the series. Compound 27 (0.25, 0.5, 1.0 mg/kg po) demonstrated dose-related cardiac stimulant activity, which was maintained for at least 4 h. No changes in heart rate were observed. Compounds 3, 4, 26, and 27 also selectively stimulated the force of contraction, rather than heart rate, in the dog heart-lung preparation. For a 50% increase in dP/dt max with 27, heart rate changed by less than 10 beats/min. In norepinephrine contracted rabbit femoral artery and saphenous vein, 27 produced dose related (5 x 10-7 to 5 x 10-4 M) vasorelaxant activity. The combined cardiac stimulant and vasodilator properties displayed by 27, coupled with a lack of effect on heart rate, should be beneficial for the treatment of congestive heart failure.